Last 12 months
Inside the activity.
0 purchase rows · 16 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 7 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 5 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 02, 2021 Filed Aug 4, 2021 22:24 UTC |
Salmon SeanEVP & Pres Diabetes/Cardiovasc
|
GrantStock Option (Right to Buy) · Derivative | 1,085 | $0.00 Strike: $131.26 | $0.00 |
DisclosureSEC source: 0001127602-21-023105 · form4.xml · derivative · entry 4 Salmon Sean · CIK 0001792380 · EVP & Pres Diabetes/Cardiovasc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,085 Underlying: Ordinary Shares · 1,085 shares Expires 2031-08-02 F4 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 22:24 UTC |
Salmon SeanEVP & Pres Diabetes/Cardiovasc
|
GrantStock Option (Right to Buy) · Derivative | 46,867 | $0.00 Strike: $131.26 | $0.00 |
DisclosureSEC source: 0001127602-21-023105 · form4.xml · derivative · entry 3 Salmon Sean · CIK 0001792380 · EVP & Pres Diabetes/Cardiovasc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,867 Underlying: Ordinary Shares · 46,867 shares Expires 2031-08-02 F4 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 22:24 UTC |
Salmon SeanEVP & Pres Diabetes/Cardiovasc
|
GrantOrdinary Shares | 5,486 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-023105 · form4.xml · nonDerivative · entry 2 Salmon Sean · CIK 0001792380 · EVP & Pres Diabetes/Cardiovasc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,329 F3 · kind: The restrictions on the award shall lapse 100% on the third anniversary of the Grant Date. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 22:24 UTC |
Salmon SeanEVP & Pres Diabetes/Cardiovasc
|
Tax withholdingOrdinary Shares | 2,272 | $131.31 | $298,336.32 |
DisclosureSEC source: 0001127602-21-023105 · form4.xml · nonDerivative · entry 1 Salmon Sean · CIK 0001792380 · EVP & Pres Diabetes/Cardiovasc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,843 F1 · balance_after: This amount has been adjusted to correct a mathematical error in exempt transactions such as dividend reinvestment. F2 · balance_after: This balance increased by 163 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 22:15 UTC |
Kirk Jennifer MChief Accounting Officer
|
GrantPerformance Share Units · Derivative | 2,857 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-023099 · form4.xml · derivative · entry 4 Kirk Jennifer M · CIK 0001613343 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,857 Underlying: Performance Share Units · 2,857 shares Expires not disclosed F4 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F5 · shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 2,857 shares will be issued. The actual number of shares to be issued could range from a low of 572 at minimum performance to a high of 5,714 shares at maximum performance. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F6 · derivative.exercise_date: Vests on August 2, 2024. F6 · derivative.expiration_date: Vests on August 2, 2024. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 22:15 UTC |
Kirk Jennifer MChief Accounting Officer
|
GrantStock Option (Right to Buy) · Derivative | 1,085 | $0.00 Strike: $131.26 | $0.00 |
DisclosureSEC source: 0001127602-21-023099 · form4.xml · derivative · entry 3 Kirk Jennifer M · CIK 0001613343 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,085 Underlying: Ordinary Shares · 1,085 shares Expires 2031-08-02 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 22:15 UTC |
Kirk Jennifer MChief Accounting Officer
|
GrantStock Option (Right to Buy) · Derivative | 9,764 | $0.00 Strike: $131.26 | $0.00 |
DisclosureSEC source: 0001127602-21-023099 · form4.xml · derivative · entry 2 Kirk Jennifer M · CIK 0001613343 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,764 Underlying: Ordinary Shares · 9,764 shares Expires 2031-08-02 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 22:15 UTC |
Kirk Jennifer MChief Accounting Officer
|
GrantOrdinary Shares | 1,143 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-023099 · form4.xml · nonDerivative · entry 1 Kirk Jennifer M · CIK 0001613343 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,387 F1 · kind: The restrictions on the award shall lapse 100% on the third anniversary of the Grant Date. F2 · balance_after: This balance increased by 140 shares due to exempt transactions such as dividend reinvestment and employee stock purchase plan. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:21 UTC |
Martha GeoffreyDirector · CEO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 11,500 | $0.00 Strike: $55.32 | $0.00 |
DisclosureSEC source: 0001127602-21-020875 · form4.xml · derivative · entry 3 Martha Geoffrey · CIK 0001560409 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,481 Underlying: Ordinary Shares · 11,500 shares Expires 2023-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: This option to purchase 1,808 Medtronic ordinary shares for $55.32 per share, which was partially vested at the effective time of the Covidien acquisition, represents the conversion of an option to purchase 1,808 Medtronic Inc. common stock shares for $55.32 per share. This Medtronic plc stock option has the same terms and conditions as the original Medtronic Inc. stock option. F5 · derivative.exercise_date: This option to purchase 20,481 Medtronic ordinary shares for $55.32 per share, which was partially vested at the effective time of the Covidien acquisition, represents the conversion of an option to purchase 20,481 Medtronic Inc. common stock shares for $55.32 per share. This Medtronic plc stock option has the same terms and conditions as the original Medtronic Inc. stock option. F6 · balance_after: This amount has been adjusted to correct a mathematical error that occurred in Column 9 in the previously filed Form 4 on April 7, 2021. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:21 UTC |
Martha GeoffreyDirector · CEO
|
SaleOrdinary Shares | 11,500 | $125.29 | $1,440,835.00 |
DisclosureSEC source: 0001127602-21-020875 · form4.xml · nonDerivative · entry 2 Martha Geoffrey · CIK 0001560409 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,948 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:21 UTC |
Martha GeoffreyDirector · CEO
|
Exercise / conversionOrdinary Shares | 11,500 | $55.32 | $636,180.00 |
DisclosureSEC source: 0001127602-21-020875 · form4.xml · nonDerivative · entry 1 Martha Geoffrey · CIK 0001560409 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,448 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: This amount has been adjusted to correct a mathematical error in exempt transactions such as dividend reinvestment. F3 · balance_after: This balance increased by 266 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| June 22, 2021 Filed Jun 28, 2021 21:21 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
GiftOrdinary Shares | 238 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-020754 · form4.xml · nonDerivative · entry 6 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Child #3 Disclosed balance after: 843 Read SEC document |
| June 22, 2021 Filed Jun 28, 2021 21:21 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
GiftOrdinary Shares | 238 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-020754 · form4.xml · nonDerivative · entry 5 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,509 Read SEC document |
| June 22, 2021 Filed Jun 28, 2021 21:21 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
GiftOrdinary Shares | 238 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-020754 · form4.xml · nonDerivative · entry 4 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Child #2 Disclosed balance after: 843 Read SEC document |
| June 22, 2021 Filed Jun 28, 2021 21:21 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
GiftOrdinary Shares | 238 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-020754 · form4.xml · nonDerivative · entry 3 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,747 Read SEC document |
| June 22, 2021 Filed Jun 28, 2021 21:21 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
GiftOrdinary Shares | 238 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-020754 · form4.xml · nonDerivative · entry 2 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Child #1 Disclosed balance after: 843 Read SEC document |
| June 22, 2021 Filed Jun 28, 2021 21:21 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
GiftOrdinary Shares | 238 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-020754 · form4.xml · nonDerivative · entry 1 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,985 Read SEC document |
| June 21, 2021 Filed Jun 22, 2021 21:58 UTC |
Wall Brett A.EVP & Pres Neuroscience
|
SaleOrdinary Shares | 115 | $123.50 | $14,202.50 |
DisclosureSEC source: 0001127602-21-020516 · form4.xml · nonDerivative · entry 3 Wall Brett A. · CIK 0001473812 · EVP & Pres Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,602 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 21:58 UTC |
Wall Brett A.EVP & Pres Neuroscience
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,168 | $0.00 Strike: $74.84 | $0.00 |
DisclosureSEC source: 0001127602-21-020516 · form4.xml · derivative · entry 4 Wall Brett A. · CIK 0001473812 · EVP & Pres Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,850 Underlying: Ordinary Shares · 1,168 shares Expires 2025-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: This option became exercisable on June 29, 2018, subject to Medtronic plc's achievement of a pre-specified cash Earnings Per Share Growth Rate for fiscal years 2016 through 2018. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 21:58 UTC |
Wall Brett A.EVP & Pres Neuroscience
|
Tax withholdingOrdinary Shares | 938 | $123.23 | $115,589.74 |
DisclosureSEC source: 0001127602-21-020516 · form4.xml · nonDerivative · entry 2 Wall Brett A. · CIK 0001473812 · EVP & Pres Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,717 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 21:58 UTC |
Wall Brett A.EVP & Pres Neuroscience
|
Exercise / conversionOrdinary Shares | 1,168 | $74.84 | $87,413.12 |
DisclosureSEC source: 0001127602-21-020516 · form4.xml · nonDerivative · entry 1 Wall Brett A. · CIK 0001473812 · EVP & Pres Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,655 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 22:11 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
SaleOrdinary Shares | 605 | $124.47 | $75,304.35 |
DisclosureSEC source: 0001127602-21-020242 · form4.xml · nonDerivative · entry 1 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,223 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: This balance increased by 272 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 22:00 UTC |
Wall Brett A.EVP & Pres Neuroscience
|
SaleOrdinary Shares | 2,473 | $128.07 | $316,717.11 |
DisclosureSEC source: 0001127602-21-018780 · form4.xml · nonDerivative · entry 3 Wall Brett A. · CIK 0001473812 · EVP & Pres Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,487 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 17:55 UTC |
Liddicoat John REVP & President of Americas
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,142 | $0.00 Strike: $88.06 | $0.00 |
DisclosureSEC source: 0001127602-21-018560 · form4.xml · derivative · entry 9 Liddicoat John R · CIK 0001752060 · EVP & President of Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 15,142 shares Expires 2026-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning one year from grant date. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 17:55 UTC |
Liddicoat John REVP & President of Americas
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,136 | $0.00 Strike: $88.06 | $0.00 |
DisclosureSEC source: 0001127602-21-018560 · form4.xml · derivative · entry 8 Liddicoat John R · CIK 0001752060 · EVP & President of Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,136 shares Expires 2026-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning one year from grant date. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 17:55 UTC |
Liddicoat John REVP & President of Americas
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,283 | $0.00 Strike: $78.00 | $0.00 |
DisclosureSEC source: 0001127602-21-018560 · form4.xml · derivative · entry 7 Liddicoat John R · CIK 0001752060 · EVP & President of Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,283 shares Expires 2025-08-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning one year from grant date. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 17:55 UTC |
Liddicoat John REVP & President of Americas
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 17,095 | $0.00 Strike: $78.00 | $0.00 |
DisclosureSEC source: 0001127602-21-018560 · form4.xml · derivative · entry 6 Liddicoat John R · CIK 0001752060 · EVP & President of Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 17,095 shares Expires 2025-08-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning one year from grant date. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 17:55 UTC |
Liddicoat John REVP & President of Americas
|
SaleOrdinary Shares | 34,656 | $126.65 | $4,389,182.40 |
DisclosureSEC source: 0001127602-21-018560 · form4.xml · nonDerivative · entry 5 Liddicoat John R · CIK 0001752060 · EVP & President of Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,551 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 17:55 UTC |
Liddicoat John REVP & President of Americas
|
Exercise / conversionOrdinary Shares | 15,142 | $88.06 | $1,333,404.52 |
DisclosureSEC source: 0001127602-21-018560 · form4.xml · nonDerivative · entry 4 Liddicoat John R · CIK 0001752060 · EVP & President of Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,207 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 17:55 UTC |
Liddicoat John REVP & President of Americas
|
Exercise / conversionOrdinary Shares | 1,136 | $88.06 | $100,036.16 |
DisclosureSEC source: 0001127602-21-018560 · form4.xml · nonDerivative · entry 3 Liddicoat John R · CIK 0001752060 · EVP & President of Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,065 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 17:55 UTC |
Liddicoat John REVP & President of Americas
|
Exercise / conversionOrdinary Shares | 1,283 | $78.00 | $100,074.00 |
DisclosureSEC source: 0001127602-21-018560 · form4.xml · nonDerivative · entry 2 Liddicoat John R · CIK 0001752060 · EVP & President of Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,929 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 17:55 UTC |
Liddicoat John REVP & President of Americas
|
Exercise / conversionOrdinary Shares | 17,095 | $78.00 | $1,333,410.00 |
DisclosureSEC source: 0001127602-21-018560 · form4.xml · nonDerivative · entry 1 Liddicoat John R · CIK 0001752060 · EVP & President of Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,646 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: This balance increased by 562 shares due to exempt transactions such as dividend reinvestment and employee stock purchase plan. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 22:00 UTC |
Wall Brett A.EVP & Pres Neuroscience
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 12,300 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001127602-21-018780 · form4.xml · derivative · entry 4 Wall Brett A. · CIK 0001473812 · EVP & Pres Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 12,300 shares Expires 2023-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 22:00 UTC |
Wall Brett A.EVP & Pres Neuroscience
|
Tax withholdingOrdinary Shares | 7,355 | $126.59 | $931,069.45 |
DisclosureSEC source: 0001127602-21-018780 · form4.xml · nonDerivative · entry 2 Wall Brett A. · CIK 0001473812 · EVP & Pres Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,960 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 22:00 UTC |
Wall Brett A.EVP & Pres Neuroscience
|
Exercise / conversionOrdinary Shares | 12,300 | $47.00 | $578,100.00 |
DisclosureSEC source: 0001127602-21-018780 · form4.xml · nonDerivative · entry 1 Wall Brett A. · CIK 0001473812 · EVP & Pres Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,315 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · balance_after: This balance increased by 300 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| May 03, 2021 Filed May 4, 2021 17:56 UTC |
OLEARY DENISE MDirector
|
GrantOrdinary Shares | 1,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-015327 · form4.xml · nonDerivative · entry 1 OLEARY DENISE M · CIK 0001145159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,745 F1 · kind: This restricted stock unit award will vest on the one year anniversary of the grant date. Read SEC document |
| May 03, 2021 Filed May 4, 2021 21:52 UTC |
Lofton Kevin EDirector
|
GrantOrdinary Shares | 820 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-015324 · form4.xml · nonDerivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 820 F1 · kind: This restricted stock unit award will vest on the one year anniversary of the grant date. Read SEC document |
| May 03, 2021 Filed May 4, 2021 21:59 UTC |
Powell Kendall JDirector
|
GrantOrdinary Shares | 1,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-015330 · form4.xml · nonDerivative · entry 1 Powell Kendall J · CIK 0001298823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,466 F1 · kind: This restricted stock unit award will vest on the one year anniversary of the grant date. Read SEC document |
| May 03, 2021 Filed May 4, 2021 21:39 UTC |
DONNELLY SCOTT CDirector
|
GrantOrdinary Shares | 1,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-015313 · form4.xml · nonDerivative · entry 1 DONNELLY SCOTT C · CIK 0001233158 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,349 F1 · kind: This restricted stock unit award will vest on the one year anniversary of the grant date. Read SEC document |
| May 03, 2021 Filed May 4, 2021 21:35 UTC |
ARNOLD CRAIGDirector
|
GrantOrdinary Shares | 1,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-015309 · form4.xml · nonDerivative · entry 1 ARNOLD CRAIG · CIK 0001188578 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,954 F1 · kind: This restricted stock unit award will vest on the one year anniversary of the grant date. Read SEC document |
| May 03, 2021 Filed May 4, 2021 17:50 UTC |
Lenehan James TDirector
|
GrantOrdinary Shares | 1,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-015322 · form4.xml · nonDerivative · entry 1 Lenehan James T · CIK 0001189009 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,849 F1 · kind: This restricted stock unit award will vest on the one year anniversary of the grant date. Read SEC document |
| May 03, 2021 Filed May 4, 2021 21:44 UTC |
HOGAN RANDALL JDirector
|
GrantOrdinary Shares | 1,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-015316 · form4.xml · nonDerivative · entry 1 HOGAN RANDALL J · CIK 0001189049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,682 F1 · kind: This restricted stock unit award will vest on the one year anniversary of the grant date. Read SEC document |
| May 03, 2021 Filed May 4, 2021 21:31 UTC |
ANDERSON RICHARD HDirector
|
GrantOrdinary Shares | 1,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-015305 · form4.xml · nonDerivative · entry 1 ANDERSON RICHARD H · CIK 0001200334 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,050 F1 · kind: This restricted stock unit award will vest on the one year anniversary of the grant date. Read SEC document |
| May 03, 2021 Filed May 4, 2021 21:47 UTC |
LEAVITT MICHAEL ODirector
|
GrantOrdinary Shares | 1,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-015318 · form4.xml · nonDerivative · entry 1 LEAVITT MICHAEL O · CIK 0001536118 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,779 F1 · kind: This restricted stock unit award will vest on the one year anniversary of the grant date. F2 · balance_after: This balance increased by 202 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| May 03, 2021 Filed May 4, 2021 21:54 UTC |
NABEL ELIZABETH GDirector
|
GrantOrdinary Shares | 1,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-015326 · form4.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,353 F1 · kind: This restricted stock unit award will vest on the one year anniversary of the grant date. Read SEC document |
| May 03, 2021 Filed May 4, 2021 21:42 UTC |
Goldsmith Andrea JoDirector
|
GrantOrdinary Shares | 1,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-015315 · form4.xml · nonDerivative · entry 1 Goldsmith Andrea Jo · CIK 0001730514 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,985 F1 · kind: This restricted stock unit award will vest on the one year anniversary of the grant date. Read SEC document |
| April 27, 2021 Filed Apr 28, 2021 18:31 UTC |
OLEARY DENISE MDirector
|
Tax withholdingOrdinary Shares | 426 | $129.97 | $55,367.22 |
DisclosureSEC source: 0001127602-21-014585 · form4.xml · nonDerivative · entry 1 OLEARY DENISE M · CIK 0001145159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,411 F1 · balance_after: This balance increased by 702 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| April 27, 2021 Filed Apr 28, 2021 22:20 UTC |
Powell Kendall JDirector
|
Tax withholdingOrdinary Shares | 426 | $129.97 | $55,367.22 |
DisclosureSEC source: 0001127602-21-014584 · form4.xml · nonDerivative · entry 1 Powell Kendall J · CIK 0001298823 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,132 F1 · balance_after: This balance increased by 494 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| April 27, 2021 Filed Apr 28, 2021 22:48 UTC |
DONNELLY SCOTT CDirector
|
Tax withholdingOrdinary Shares | 426 | $129.97 | $55,367.22 |
DisclosureSEC source: 0001127602-21-014590 · form4.xml · nonDerivative · entry 1 DONNELLY SCOTT C · CIK 0001233158 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,015 F1 · balance_after: This balance increased by 83 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| April 27, 2021 Filed Apr 28, 2021 18:37 UTC |
Lenehan James TDirector
|
Tax withholdingOrdinary Shares | 426 | $129.97 | $55,367.22 |
DisclosureSEC source: 0001127602-21-014587 · form4.xml · nonDerivative · entry 1 Lenehan James T · CIK 0001189009 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,515 F1 · balance_after: This balance increased by 514 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.